Here is a thing that happened while I was researching another article. I asked two different AI assistants whether the first dose of allergy drops must be taken in a doctor’s office. One said yes and cited four sources including a national allergy organization. The other said no and put the supervised first dose in a column labeled tablets, where it belongs.

Same question. Same day. Opposite answers. And a reader has no way to tell which is which.

That isn’t a story about AI. It’s a story about a confusion that has been a part of this subject for twenty years. AI has just scaled it up. Allergy drops, shots and tablets are three different treatments, all of them immunotherapy, and they get written about as though they were one thing, and most of the contradictory material you’ll find about allergy drops turns out to be a true statement about one of the other two.

The quick answer. Allergy shots, sublingual tablets and aqueous sublingual drops share their extracts and their basic mechanism. They differ in dose, in how they’re delivered, in regulatory status, and in reaction risk.

Rules written for one get applied to the others constantly, in both directions. One question resolves most of what confuses people: what were they actually writing about?

Below are eight cases where the answer is the difference between helpful advice and incorrect information, including one that runs against us and one where the mistake was mine.

I’ve used allergy drops since 2003 and treated allergies since 1991, and over those years our practice has treated more than 15,000 patients with drops. I’ve also made this mistake in print, which is case four, and I’d rather show you that than pretend the problem only belongs to other people.

Two ways it goes wrong

Almost every case falls into one of two patterns and naming them makes the rest easier to spot.

The first is route transfer. Something genuinely true of allergy shots, or of the FDA-approved tablets, gets applied to drops because all three are immunotherapy. The statement is accurate about its own subject and misleading about yours.

The second is a regulatory artifact. A line written to satisfy a labeling requirement, or to define where self-treatment ends and a clinician should get involved, gets read as a medical fact about your body. These lines are written by lawyers and regulators for reasons that have nothing to do with what’s safe at month seven versus month six.

Case one: the supervised first dose

This is the one I opened with, and it’s the most common.

The FDA-approved sublingual tablets carry labeling that calls for the first dose to be taken with a clinician present and for an epinephrine auto-injector to be prescribed, because rare reactions have followed a first tablet. (1, 2) That’s a real requirement, it applies to those products, and it exists for a reason.

Aqueous drops are a different preparation at a different dose. They’re started at home after a proper evaluation, which is standard practice among the physicians who prescribe them. But because both go under the tongue, the tablet rule gets repeated as though it described all sublingual treatment.

In the answers I looked at, one assistant asserted the supervised first dose for both routes and cited several respectable sources for it. Another put it only in the tablet column. Both were reporting accurately on something. Only one was answering the specific question that had been asked.

What the confusion costs a reader: they conclude that at-home treatment is cutting a corner. It isn’t. The supervised first dose exists because rare reactions have followed a first tablet, and the tablets carry a boxed warning to match. Drops carry neither, which is why they’re started differently.

Case two: start three months before your season

You will read that immunotherapy should be started well before your pollen season, sometimes twelve weeks or more ahead.

That’s a property of the approved tablets. Their starting schedules are built around the relevant pollen season and written into their labeling. Aqueous drops have no season-based starting protocol. Nothing about how we start changes if you walk in during the worst week of a bad season.

What the confusion costs a reader: someone miserable in September concludes they have missed their window and should wait until winter, which costs them a season of relief for nothing. Our piece on starting drops mid-season works through that in full.

Case three: beta blockers and epinephrine

This is the most consequential one, and it’s route transfer from the injected literature.

The concern is specific: if you have anaphylaxis from allergy treatment, a beta blocker might blunt how well epinephrine works to rescue you. (3) That’s legitimate. With allergy shots, systemic reactions are uncommon but real, which is why offices are equipped for them. The approved tablets carry a boxed warning for severe allergic reactions, which is why they require that supervised first dose. With aqueous drops, a reaction of that kind is close to a theoretical event. Across the roughly sixty randomized controlled trials of sublingual immunotherapy pooled in the Cochrane review, no anaphylaxis was reported.

Our own academy’s 2024 guideline reflects that difference. It says clinicians may choose not to start immunotherapy in patients taking beta blockers, and it offers that as an Option, the weakest strength a guideline statement carries, explicitly leaving the decision to the clinician. It’s a judgment, not a prohibition.

But in one of the AI answers I looked at, beta blockers appeared in a list of people who should be cautious or avoid drops, sitting alongside uncontrolled asthma and a history of severe reactions. Those two are correct and we enforce them. The third is imported. Three items in a list, two right and one wrong, is exactly how this kind of error survives contact with a careful reader.

And there’s a further layer here that took me by surprise, which is that sublingual immunotherapy isn’t one safety category either. Anaphylaxis to any form of it is vanishingly rare, estimated across three decades of use at roughly one case per hundred million doses taken. (4,5) But when European drug regulators looked at the suspected cases reported for dust mite treatment between 2016 and 2019, 82 reports in total, 54 of them involved one particular kind of product: high-dose tablets made from native extract and started at full strength, with no gradual buildup.(4)

The remaining 28 involved other preparations, including oral solutions and drops. So the signal in that data isn’t the sublingual route. (4) It’s the starting dose, and the absence of any escalation. Which means a reader who correctly learns to separate drops from shots, and then treats everything sublingual as one thing, has made a smaller version of the same mistake.

What the confusion costs a reader: an older patient on a blood pressure medication gets told they aren’t a candidate for a treatment that might have helped them. Our piece on allergy drops after 65 exists largely because of this.

Case four: the one I got wrong

Now mine, because you should see that this isn’t a problem confined to other people.

While writing an article about starting drops during allergy season, I wanted to establish that easing a dose during a heavy pollen stretch is normal practice rather than something we improvise. So I cited national immunotherapy guidance stating that maintenance doses may be reduced, and shouldn’t be increased, during periods of heavy natural exposure. All accurate.

What I didn’t say was that this guidance is written mainly around the risk of a systemic reaction, which is primarily a shots and tablets concern. A reader following that citation would reasonably conclude I was worried about something that barely happens with drops. I had cited a rule from another route without saying which route it was written for, which is the exact mistake this article is about.

It was caught in review before publication and the paragraph was rewritten to say why the guidance was being cited and to put the drops-specific evidence beside it. We also added a rule to our own standards requiring it, and a line to our pre-publication checklist. I’m telling you this because a piece like this one, written by people who sell drops and cataloguing other people’s errors, would deserve your suspicion. Including ours is the least I can do about that.

Case five: the six-month line on the box

This one is a regulatory artifact rather than a route transfer, and it applies to a medication most people reading this also take.

Over-the-counter steroid nasal spray labels tell adults to ask a doctor before using the spray daily for more than six consecutive months. People read that, count the years they have been spraying, and conclude they may have done something harmful to themselves.

That line is a self-treatment boundary. It marks where the manufacturers think a clinician should be involved, in exactly the way other over-the-counter labels do. It isn’t a point at which anything changes in your body, and it isn’t evidence that month seven is riskier than month six. Our piece on long-term nasal steroid use goes through what the evidence actually shows.

Case six: a week either side of a vaccine

This is the newest one, and it turned up while I was writing about drops and vaccinations.

You may have been told to leave a week between your allergy treatment and a vaccine, on both sides. That instruction is real, and it was written about allergy shots.

A position paper from two German allergy societies, written during the COVID vaccination campaign, recommends a week either side for injections. (6) For sublingual and oral treatment it’s much lighter: take them up to the day before, with a break of two to seven days afterward. In our practice we go further and don’t ask people to stop at all. That’s our clinical judgment, not a published rule, and if you’d rather leave a day or two, that’s reasonable too.

What the confusion costs a reader: someone stops their drops for two weeks every flu season, or puts off a vaccine to protect their allergy schedule. Neither is necessary, and the second is a real loss. Our piece on drops before surgery and vaccines goes through the reasoning, including the one concern that’s actually written down and what is and isn’t known about it.

Case seven: under the tongue is a place, not a treatment

This one is happening right now, and it’s a different shape from the others. Nothing is being transferred from one treatment to another. Two unrelated products are simply sharing a word with ours.

Two sublingual products are in the allergy news this year, and neither is allergy drops. The first is a peanut tablet that dissolves under the tongue, designed to treat peanut allergy. It completed a mid-stage trial in 2026, and a larger trial is planned. (7,8) The second is an epinephrine film that dissolves under the tongue, a needle-free way to treat a severe allergic reaction once it’s happening. (9) The FDA didn’t approve its first application in January 2026, citing the packaging and how people placed the film, and a resubmission is now under review with a decision expected in March 2027. (9)

Sublingual tells you where something dissolves. It doesn’t tell you what it is. The peanut tablet is food allergy treatment, and food allergy isn’t something we treat; treating airborne allergies does nothing for it. The epinephrine film is a rescue medicine, not immunotherapy at all.

What the confusion costs a reader: a parent of a peanut-allergic child reads about a sublingual peanut tablet and concludes that allergy drops might help with the peanut allergy too. They won’t, and food allergy is a place where a mistaken belief can be dangerous. If peanut allergy is the question, the right person is an allergist who treats food allergy.

Case eight: the one that runs against us

If the pattern only ever made drops look better, you should stop reading. It doesn’t.

Eosinophilic esophagitis, an inflammatory condition of the esophagus, is listed in the guideline as a contraindication applying to sublingual immunotherapy specifically, with allergy shots remaining available to those patients. (10) The reason is straightforward: drops get swallowed and shots don’t.

So here the direction reverses. Someone reading general immunotherapy safety material would come away thinking this risk is shared across routes, and it isn’t. It belongs to ours. If you’ve been diagnosed with it, or if you develop difficulty swallowing or the sensation of food sticking while on drops, that’s a reason to stop and be examined rather than a footnote. Our piece on who shouldn’t take allergy drops carries the full list.

Why two good sources disagree on the same day

It’s worth understanding why this happens, because it tells you what to do about it.

None of the sources in the case above were making things up. The organization whose page was cited for the supervised first dose was describing tablets accurately on a page about tablets.

The trouble comes at the summarizing layer, where material about three related treatments gets pooled and averaged into a single answer, and the qualifier that made each statement true gets dropped as redundant.

That’s also how it happens in a doctor’s office, and in articles, and in my own writing. The mechanism isn’t artificial intelligence. It’s compression.

Which means the fix isn’t to distrust any particular source. It’s to notice when a qualifier is missing.

The check, in three questions

Here is what I’d actually do with anything you read about this subject, including this article.

First: does the source say which treatment it means? Immunotherapy, sublingual immunotherapy and allergy drops aren’t interchangeable terms. A page that uses them as though they were is pooling three things, and you can’t tell which one any given sentence came from. A source that keeps them separate, the way one of those AI comparison tables did, is doing something more difficult and more useful.

Second: if it cites a rule, a label or a guideline, was that rule written for the treatment being discussed? Labels belong to products. Tablet labeling describes tablets. Over-the-counter labeling describes what’s safe without a clinician. A rule quoted without its subject is not a rule, it is a fragment.

Third: does the source tell you what it doesn’t know? This field has real gaps. Nobody has run a dose-ranging trial of multi-allergen liquid drops. Nobody has measured how quickly relief arrives in older patients. A source that has an answer for everything has stopped distinguishing between what’s established and what’s inferred, and that’s the same failure stated differently.

What to do next

If you’re trying to decide something specific, the useful move is narrower than reading more. Write down the question you actually have, then check whether what you’re reading is about your treatment, at your dose, in your situation. Most of the contradictions dissolve at that point.

And if they don’t, that’s a reasonable thing to bring to a physician rather than to another search. Not because you shouldn’t research this, but because the part you can’t do from a screen is apply it to yourself, and that’s where most of the value is anyway.

Start overcoming your allergies.

Get our free allergy test kit

A note to close

At Quello, we spend a surprising amount of our time untangling things people read that were true about something else. We’re a doctor-led allergy practice, born from the heritage of Advanced ENT and Allergy Center in Colorado, and we treat allergies from home with allergy drops at the center of what we do.

Since 2003, our practice has treated more than 15,000 patients with allergy drops, and I’ve been the one physician here through all of it, long enough to know that most of what confuses people about this treatment isn’t wrong, it’s just about something else.

What we work toward, for the people it fits, is what we think of as allergy freedom, a life where your allergies, and your allergy medicines, stop setting the terms.

And if you want to think it through, we’re here for you, wherever you are. Schedule your free consultation today. 

Frequently asked questions

Do I have to take my first dose of allergy drops in a doctor’s office?

No, and this is the most commonly transferred rule in the subject. The requirement for a supervised first dose with an epinephrine auto-injector prescribed belongs to the FDA-approved sublingual tablets and their labeling, because rare reactions have followed a first tablet.

Aqueous drops are a different preparation at a different dose and are started at home after a proper evaluation. You will find sources asserting the supervised first dose for both, sometimes citing reputable organizations whose pages were describing tablets. Screening before starting isn’t optional, but the in-office first dose is a tablet rule.

Are allergy drops and allergy tablets the same thing?

Both are sublingual immunotherapy and both go under the tongue, which is why they get pooled. They differ in ways that matter. Tablets are FDA-approved, standardized, fixed-dose, and treat one allergen each, with no tree pollen tablet available.

Drops are compounded to an individual’s testing and history, can cover several allergens at once, and are used off-label in the United States, which is legal and common but means they’re generally not insurance-covered. Because they differ in dose and delivery, rules written for one frequently don’t describe the other.

Can I take allergy drops if I’m on a beta blocker?

In our judgment usually yes, though this is a genuine clinical judgment rather than a settled rule and thoughtful colleagues land differently. The concern is that a beta blocker could blunt how well epinephrine works if someone had anaphylaxis, which carries real weight with allergy shots.

With aqueous drops a systemic reaction of that kind is close to a theoretical event; across roughly sixty randomized trials pooled in the Cochrane review, no anaphylaxis was reported. The 2024 AAO-HNS guideline offers this as an Option, the weakest guideline strength, which explicitly leaves the decision to the clinician.

Should I start allergy drops months before my allergy season?

You can start any time, and the starting protocol doesn’t change. Season-based starting schedules, including advice to begin twelve weeks or more ahead, are a property of the FDA-approved tablets and their labeling rather than of aqueous drops. What does change if you start mid-season is the attention paid to the rest of your medicines. The reason not to wait is different: treatment takes most of a year to produce meaningful improvement, so waiting until the season ends mostly costs you a season.

Why do different sources give me opposite answers about allergy drops?

Usually because they’re describing different treatments and not saying so. Allergy shots, sublingual tablets and aqueous drops share extracts and mechanism and differ in dose, delivery, regulation and reaction risk. A statement can be entirely accurate about one and misleading about another, and the qualifier that made it true tends to get dropped when material gets summarized. Ask three questions: does the source say which treatment it means; if it cites a rule or a label, was that rule written for that treatment; and does the source say what it doesn’t know.

Is there anything that’s riskier with drops than with shots?

Yes, and it should be said plainly given everything else here. Eosinophilic esophagitis, an inflammatory condition of the esophagus, is listed as a contraindication applying to sublingual immunotherapy specifically, with shots remaining available to those patients, for the simple reason that drops are swallowed. If you have that diagnosis, or develop difficulty swallowing or a sensation of food sticking while on drops, that’s a reason to stop and be examined rather than a footnote.

Is the sublingual peanut tablet or epinephrine film the same thing as allergy drops?

No. Both dissolve under the tongue, and that’s all they share with allergy drops. The peanut tablet is an investigational treatment for peanut allergy, still in clinical trials as of October 2026. The epinephrine film is a needle-free rescue medicine for treating a severe allergic reaction, under FDA review as of the same date. Allergy drops treat airborne allergies such as pollen and dust mite, and they do nothing for food allergy. If your question is about peanut allergy, the right person is an allergist who treats food allergy.

How do I know whether an article about allergy drops is reliable?

Look for three things. Whether it names which treatment it’s discussing rather than using immunotherapy, sublingual immunotherapy and allergy drops interchangeably. Whether any rule or label it cites was written for that treatment, since labels belong to products and a rule quoted without its subject is a fragment. And whether it tells you what it doesn’t know, because this field has real gaps and a source with an answer for everything has stopped separating what’s established from what’s inferred.